PHVS
Bearish signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Pharvaris N.V.
- Nom
- Pharvaris N.V.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 148
- PDG
- Berndt Modig
- Site web
- https://pharvaris.com
- Marché
- BCRXBMRNPHARRLYBTVTXVERA
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 301 012 titres (~10 774 771,23 $ US)
- Insiders
- Monges VivianeSchikan Johannes Gerardus Christiaan PetrusBjork ElisabethGlassman RobertModig Berndt
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$18,698,716
Avg sell (VWAP, 90d window) $36.34 vs last close $30.66 (-15.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,186,814 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-23
- Liquidity
- Liquid $21,650,156/day · 20d vol
- Last synced
-
2026-10-21 21:10:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-23 | Monges Viviane | Sell · S | 11,969 | $33.05 | $395,524 | Form 4 |
| 2026-09-22 | Schikan Johannes Gerardus Christiaan Petrus | Sell · S | 800 | $36.19 | $28,952 | Form 4 |
| 2026-09-21 | Nassif David W. | Sell · S | 6,000 | $36.47 | $218,801 | Form 4 |
| 2026-09-17 | Bjork Elisabeth | Sell · S | 52,500 | $37.89 | $1,989,409 | Form 4 |
| 2026-09-17 | Glassman Robert | Sell · S | 14,493 | $38.56 | $558,812 | Form 4 |
| 2026-09-17 | Lesage Anne | Sell · S | 20,000 | $38.27 | $765,466 | Form 4 |
| 2026-09-17 | Lu Peng | Sell · S | 100,000 | $35.00 | $3,500,000 | Form 4 |
| 2026-09-17 | Schikan Johannes Gerardus Christiaan Petrus | Sell · S | 200,000 | $35.00 | $7,000,000 | Form 4 |
| 2026-09-15 | Abele Stefan Andreas | Sell · S | 1,400 | $39.24 | $54,938 | Form 4 |
| 2026-09-15 | Glassman Robert | Sell · S · 10b5-1 | 8,667 | $38.27 | $331,716 | Form 4 |
| 2026-09-15 | Souverijns Wim | Sell · S · 10b5-1 | 6,090 | $38.99 | $237,449 | Form 4 |
| 2026-09-14 | Souverijns Wim | Sell · S · 10b5-1 | 20,000 | $39.31 | $786,126 | Form 4 |
| 2026-09-14 | Modig Berndt | Sell · S · 10b5-1 | 2,291 | $39.40 | $90,276 | Form 4 |
| 2026-09-11 | Lu Peng | Sell · S · 10b5-1 | 15,000 | $40.13 | $601,947 | Form 4 |
| 2026-09-10 | Lesage Anne | Sell · S · 10b5-1 | 30,000 | $38.30 | $1,149,084 | Form 4 |
| 2026-09-09 | Glassman Robert | Sell · S · 10b5-1 | 8,000 | $37.55 | $300,396 | Form 4 |
| 2026-09-08 | Lu Peng | Sell · S · 10b5-1 | 15,000 | $40.68 | $610,134 | Form 4 |
| 2026-08-14 | Modig Berndt | Sell · S · 10b5-1 | 2,292 | $34.77 | $79,686 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
PHVS presents a compelling clinical catalyst — positive Phase 3 Lancet publication for deucrictibant in HAE — that partially offsets its pre-revenue, cash-burning fundamentals; the strong liquidity score (85) provides a…
The first sentence of the analysis written for PHVS on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 10.11 · operating margin 0.0%
Suggested stop 26.93, nearest stored support minus 0.5 ATR(12.2% under the last close). Reward/risk to the next stored resistance is 0.09. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-08 Phase 3 Study Results Highlighting Deucrictibant''s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).
- 2026-10-05 Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
- 2026-09-22 Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.56, for a total transaction of $558,850.08. Following the sale, the director owned 10,500 shares of the company''s stock, valued at $404,880. The
- 2026-09-22 Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 20,000 shares of the company''s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $38.27, for a total transaction of $765,400.00. Following the completion of the sale, the insider directly owned 73,969 shares in the company,
- 2026-09-16 Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company''s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued
- 2026-09-16 Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the company''s stock after selling 51,755 shares during the period. Squarepoint Ops LLC owned approximately 0.07% of Pharvaris
- 2026-09-15 Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 PHVS Stock Rises 10% in a Month: What Is Driving the Rally? Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
- 2026-09-09 Pharvaris: ''Strong Buy'' Based On Deucrictibant PDUFA And Prophylaxis Trial Win Pharvaris N.V. maintains a ''Strong Buy'' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p
- 2026-09-08 Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 10.106 | 12.597 | 27.245 | 9.155 | 30.283 | |
| Quick Ratio | 10.106 | 12.597 | 27.245 | 8.933 | 30.283 | |
| Solvency Ratio | -5.808 | -5.673 | -6.870 | -4.124 | -5.976 | |
| Cash Ratio | 9.853 | 12.219 | 26.792 | 8.880 | 29.966 | |
| Price To Earnings Ratio | -7.952 | -7.465 | -9.649 | -4.628 | -8.975 | |
| Price To Earnings Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Forward Price To Earnings Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Price To Earnings Diluted Ratio | -7.952 | -7.465 | -9.649 | -4.628 | -8.975 | |
| Price To Earnings Diluted Growth Ratio | -0.402 | 1.309 | -0.608 | -0.076 | -0.136 | |
| Price To Book Ratio | 5.151 | 3.735 | 2.537 | 2.364 | 1.878 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -10.181 | -8.288 | -10.460 | -5.244 | -8.604 | |
| Price To Operating Cash Flow Ratio | -10.193 | -8.325 | -10.470 | -5.254 | -8.629 | |
| Debt To Assets Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Debt To Equity Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Debt To Capital Ratio | 0.003 | 0.003 | 0.001 | 0.003 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.111 | 1.088 | 1.038 | 1.124 | 1.035 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.630 | -5.229 | -6.372 | -3.685 | -6.384 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.004 | 1.001 | 1.002 | 1.003 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,416.998 | -152.330 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -5,384.328 | -194.617 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -176.460 | -139.448 | -389.482 | -153.753 | -178.268 | |
| Capital Expenditure Coverage Ratio | -832.672 | -223.255 | -1,034.063 | -540.344 | -342.990 | |
| Dividend Paid And Capex Coverage Ratio | -832.672 | -223.255 | -1,034.063 | -540.344 | -342.990 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.384 | -4.952 | -5.858 | -2.212 | -4.154 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 10.106 | ▼-2.491 | ▼-7.772 |
| Quick Ratio | 10.106 | ▼-2.491 | ▼-7.727 |
| Solvency Ratio | -5.808 | ▼-0.135 | ▼-0.118 |
| Cash Ratio | 9.853 | ▼-2.366 | ▼-7.689 |
| Price To Earnings Ratio | -7.952 | ▼-0.487 | ▼-0.218 |
| Price To Earnings Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Forward Price To Earnings Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Price To Earnings Diluted Ratio | -7.952 | ▼-0.487 | ▼-0.218 |
| Price To Earnings Diluted Growth Ratio | -0.403 | ▼-1.711 | ▼-0.420 |
| Price To Book Ratio | 5.151 | ▲1.416 | ▲2.018 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -10.181 | ▼-1.893 | ▼-1.626 |
| Price To Operating Cash Flow Ratio | -10.193 | ▼-1.869 | ▼-1.619 |
| Debt To Assets Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Debt To Equity Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Debt To Capital Ratio | 0.003 | ▼-0.000 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.111 | ▲0.023 | ▲0.032 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.630 | ▲0.599 | ▲0.630 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.003 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲1113.866 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲1115.789 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -176.460 | ▼-37.012 | ▲31.022 |
| Capital Expenditure Coverage Ratio | -832.672 | ▼-609.417 | ▼-238.007 |
| Dividend Paid And Capex Coverage Ratio | -832.672 | ▼-609.417 | ▼-238.007 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.384 | ▼-1.432 | ▼-1.672 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.40B | $1.00B | $974.2M | $352.9M | $384.8M | |
| Enterprise value | $1.11B | $720.2M | $583.2M | $191.5M | $175.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -8.07x | -6.00x | -6.27x | -2.85x | -3.94x | |
| EV / Free cash flow | -8.06x | -5.97x | -6.26x | -2.85x | -3.93x | |
| EV / EBITDA | -6.38x | -4.95x | -5.86x | -2.21x | -4.15x | |
| Net debt / EBITDA | 1.68x | 1.93x | 3.93x | 1.86x | 4.94x | |
| Current ratio | 10.11x | 12.60x | 27.25x | 9.15x | 30.28x | |
| Income quality | 0.79x | 0.91x | 0.93x | 0.89x | 1.04x | |
| Graham net-net | $4 | $5 | $10 | $4 | $7 | |
| Tax burden | 101.1% | 101.4% | 101.1% | 100.9% | 100.2% | |
| Interest burden | 100.0% | 90.9% | 100.0% | 87.2% | 100.7% | |
| Working capital | $269.6M | $266.4M | $383.2M | $148.6M | $204.6M | |
| Invested capital | $271.0M | $267.9M | $383.7M | $149.2M | $204.9M | |
| Return on assets | -58.3% | -46.1% | -25.3% | -45.5% | -20.1% | |
| Operating ROA | -57.3% | -42.2% | -34.2% | -45.7% | -34.6% | |
| Return on tangible assets | -58.3% | -46.1% | -25.3% | -45.5% | -20.1% | |
| Return on equity | -64.8% | -50.1% | -26.3% | -51.1% | -20.8% | |
| Return on invested capital | -62.4% | -54.2% | -25.2% | -57.9% | -26.4% | |
| Return on capital employed | -62.5% | -54.3% | -25.2% | -58.0% | -26.4% | |
| Earnings yield | -12.6% | -13.4% | -10.4% | -21.6% | -11.1% | |
| Free cash flow yield | -9.8% | -12.1% | -9.6% | -19.1% | -11.6% | |
| Capex / Op. cash flow | -0.1% | -0.4% | -0.1% | -0.2% | -0.3% | |
| Capex / Depreciation | 39.3% | 199.6% | 34.9% | 81.3% | 168.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years